ReviewOncology letters2020
Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress.
Review in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects.Frontiers in immunology · 2026Review
- Mechanisms and therapeutic strategies for immunotherapy resistance in gastric cancer.Cancer cell international · 2025Review
- Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma.The Indian journal of medical research · 2025Article
- Gastric Signet Ring Cell Carcinoma: Tumor Microenvironment Reprogramming and Novel Therapeutic Targets With Emphasis on GRIN2D.Clinical and translational science · 2025Review
- Observational
- Continuous prediction for tumor mutation burden based on transcriptional data in gastrointestinal cancers.BMC medical informatics and decision making · 2024Article
- The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer.Scientific reports · 2024Article
- Identification of a new gene signature for prognostic evaluation in cervical cancer: based on cuproptosis-associated angiogenesis and multi-omics analysis.Cancer cell international · 2024Article
- Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer.Therapeutic advances in medical oncology · 2024Review
- Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology.Journal of cellular and molecular medicine · 2023Article
- Article
- An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.Journal of healthcare engineering · 2022Article
- Neoadjuvant/Perioperative Treatment Affects Spatial Distribution and Densities of Tumor Associated Neutrophils and CD8+ Lymphocytes in Gastric Cancer.Journal of personalized medicine · 2021Article
- Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report.Annals of translational medicine · 2021Article
- A Network Pharmacology Study Based on the Mechanism of Citri Reticulatae Pericarpium-Pinelliae Rhizoma in the Treatment of Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer.Disease markers · 2021Article
- Oncoimmunology Meets Organs-on-Chip.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the most common types of cancer; notably, gastric cancer is one of the top five malignancies with regards to incidence and mortality rates. The symptoms of early gastric cancer are not typical, exhibiting only slight upper abdominal discomfort. When the symptoms become more obvious, the lesion has usually progressed to an advanced stage. Notably, >90% of inpatients already have locally advanced or metastatic gastric cancer at the time of initial diagnosis, with limited treatment options for advanced gastric cancer. These options include chemotherapy, targeted therapy and immune checkpoint inhibitors (ICIs). With regards to ICIs, the clinical benefit of monotherapy for advanced gastric cancer is limited; however, combinations of ICIs and other therapies may have clinical benefit. Relevant clinical studies have demonstrated that combinations of ICIs with chemotherapy, anti-vascular targeted therapy or other molecular targeted therapies, and the use of two ICIs, improve outcomes for patients with advanced gastric cancer. This article is a review of progress in the use of ICIs in combination with other therapies for the treatment of gastric cancer. The purpose of this article was to advance gastric cancer immunotherapy and to improve the overall therapeutic benefit for patients with advanced gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.